Innoviva, Inc. (INVA)

US — Healthcare Sector
Peers: MDXG  SANA  RLAY  SEPN  PRME  UPB  SPRY  NKTR  ZBIO  PRAX 

Automate Your Wheel Strategy on INVA

With Tiblio's Option Bot, you can configure your own wheel strategy including INVA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol INVA
  • Rev/Share 5.8893
  • Book/Share 11.3707
  • PB 1.5188
  • Debt/Equity 0.6308
  • CurrentRatio 2.6435
  • ROIC 0.0012

 

  • MktCap 1088372912.0
  • FreeCF/Share 3.1233
  • PFCF 5.5432
  • PE 28.0907
  • Debt/Assets 0.3381
  • DivYield 0
  • ROE 0.0568

 

  • Rating B+
  • Score 3
  • Recommendation Neutral
  • P/E Score 2
  • DCF Score 5
  • P/B Score 4
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation INVA Goldman -- Sell -- $17 Sept. 30, 2025
Initiation INVA Oppenheimer -- Outperform -- $45 Aug. 11, 2025
Initiation INVA H.C. Wainwright -- Buy -- $40 July 14, 2025
Initiation INVA Cantor Fitzgerald -- Overweight -- $26 July 11, 2025
Initiation INVA Scotiabank -- Sector Outperform -- $55 March 7, 2025

News

Antheia Appoints Eric d'Esparbes as Chief Financial Officer
INVA
Published: October 21, 2025 by: PRNewsWire
Sentiment: Neutral

d'Esparbes to lead Antheia's financial strategy as the company continues its global expansionand commercialization MENLO PARK, Calif. , Oct. 21, 2025 /PRNewswire/ -- Antheia , the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, today announced the appointment of Eric d'Esparbes as Chief Financial Officer.

Read More
image for news Antheia Appoints Eric d'Esparbes as Chief Financial Officer
Are Investors Undervaluing Innoviva (INVA) Right Now?
INVA
Published: October 07, 2025 by: Zacks Investment Research
Sentiment: Positive

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Read More
image for news Are Investors Undervaluing Innoviva (INVA) Right Now?
Innoviva to Participate in Upcoming Investor Conferences
INVA
Published: June 03, 2025 by: Business Wire
Sentiment: Neutral

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in June: Goldman Sachs 46th Annual Global Healthcare Conference 2025 Form.

Read More
image for news Innoviva to Participate in Upcoming Investor Conferences
Billionaire Healthcare Investor Alex Denner's Hedge Fund Has 75% of Its Assets in These 3 Stocks
INVA, IRWD, NBIX
Published: March 17, 2025 by: 24/7 Wall Street
Sentiment: Neutral

If you work in the biotech industry, you might know the name Alex Denner.

Read More
image for news Billionaire Healthcare Investor Alex Denner's Hedge Fund Has 75% of Its Assets in These 3 Stocks
Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress
INVA
Published: February 26, 2025 by: Business Wire
Sentiment: Neutral

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the fourth quarter and full year ended December 31, 2024, and highlighted select corporate progress and achievements. Pavel Raifeld,.

Read More
image for news Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress

About Innoviva, Inc. (INVA)

  • IPO Date 2004-10-05
  • Website https://www.inva.com
  • Industry Biotechnology
  • CEO Pavel Raifeld
  • Employees 127

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.